SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001346302-21-000037
Filing Date
2021-04-29
Accepted
2021-04-29 16:22:30
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2021proxystatementdefa14a.htm DEFA14A 20449
2 xersfinalnaa0011.jpg GRAPHIC 181779
3 xersfinalnaa0021.jpg GRAPHIC 53073
  Complete submission text file 0001346302-21-000037.txt   344980
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38536 | Film No.: 21871003
SIC: 2834 Pharmaceutical Preparations